News

In this new role, Dr Mueller will expand his leadership responsibilities to cover all of Vertex’s global R&D, including clinical and non-clinical development, clinical operations, medical and regulatory

According to Invitrogen, Dynabeads SSEA-4 addresses a key challenge in translational research by separating undifferentiated stem cells from those that are differentiated. Scientists from Invitrogen and the Buck

The expansion is being led by Reiko Nishiguchi, sales director, to provide sales, technology, service and marketing support throughout Asia via a multi-lingual staff. The new office is

Spear is an international, multi-center, randomized, controlled, pivotal Phase III trial of picoplatin in patients with small cell lung cancer (SCLC) who were refractory to or progressed within

The suit, filed in US District Court for the Western District of Wisconsin, asserts that Affymetrix’s GeneChip HT array plate and GeneChip HT array plate scanner infringe upon

According to Merck, launches in other European countries are expected to take place in the coming months, once individual marketing authorizations are granted. Bioequivalent to the existing Glucophage

As of March 31, 2009, Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) of $40.7 million. “During the first four months

Looking forward for the full year 2009, the company anticipates that its reported revenues will be between a 1% decline and 1% growth over 2008. Excluding a 4%

Operating expenses decreased to $10.6 million for the first quarter of 2009 from $12.0 million for the first quarter of 2008, primarily as a result of a strategic